["Magic bullets"--monoclonal antibodies in acute leukemia and non-Hodgkin's lymphoma treatment].
Because of high percent of failures in haematologic malignancies treatment there is a need of discovering new drugs. One of the new approaches are monoclonal antibodies, which target specific cluster differentiation antigens on tumor cells. Rituximab is an anti-CD20 antibody used in non-Hodgkin lymphoma, alemtuzumab--in B chronic lymphocytic leukaemia, gemtuzumab ozogamicin--in non-lymphoblastic leukaemia, tositumomab and ibritumomab are monoclonal antibodies binded with radiopharmaceutics and are used in non-Hodgkin lymphomas.
Łuczyński
Włodzimierz
W
Klinika Onkologii Dzieciecej Akademii Medycznej, Białymstoku.
Krawczuk-Rybak
Maryna
M
D000074323:Alemtuzumab; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D002051:Burkitt Lymphoma / Q000188:drug therapy*; D000079982:Gemtuzumab; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D000069283:Rituximab
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab; D000069283:Rituximab; D000079982:Gemtuzumab